07:39 AM EDT, 06/11/2024 (MT Newswires) -- Sage Therapeutics ( SAGE ) said Tuesday that its phase 2 SURVEYOR trial met its primary endpoint, exhibiting a statistically significant difference between healthy participants and patients with Huntington's disease before treatment with the investigational drug dalzanemdor or placebo.

Dalzanemdor was found to be safe and generally well-tolerated in the trial, which was expected to assess the safety and tolerability as a secondary objective, the company said.

Sage Therapeutics ( SAGE ), which enrolled 40 Huntington's disease patients and 29 healthy participants, said it now intends to report topline results from its LIGHTWAVE trial in mild cognitive impairment and mild dementia in Alzheimer's Disease alongside topline results from the DIMENSION trial in cognitive impairment associated with Huntington's disease.

Price: 10.98, Change: +0.08, Percent Change: +0.73